Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.21 EUR
Change Today +0.018 / 0.82%
Volume 0.0
HQ8A On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:26 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (HQ8A) Snapshot

Open
€2.20
Previous Close
€2.19
Day High
€2.24
Day Low
€2.17
52 Week High
03/19/15 - €3.41
52 Week Low
12/3/14 - €1.90
Market Cap
42.6M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
19.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LPATH INC-CLASS A (HQ8A)

Related News

No related news articles were found.

lpath inc-class a (HQ8A) Related Businessweek News

No Related Businessweek News Found

lpath inc-class a (HQ8A) Details

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating a range of human diseases primarily in the United States. The company’s lead product candidate includes iSONEP, a monoclonal antibody against sphingosine-1-phosphate (S1P), which has completed Phase I clinical trials to treat wet age-related macular degeneration; and is in Phase 1b/2a clinical trials to treat retinal pigment epithelium detachment. Its products under development also comprise ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid S1P that is in Phase 2a clinical trials for the treatment for renal cell carcinoma; various forms of cancer; and other angiogenic-related and inflammatory-oriented indications. In addition, the company is developing Lpathomab, a mAb against lysophosphatidic acid, which is in pre-clinical trials intended for the treatment of neuropathic pain, traumatic brain injury, spinal cord injury, and fibrosis cancer. It has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

25 Employees
Last Reported Date: 03/24/15

lpath inc-class a (HQ8A) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $365.3K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $215.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $215.4K
Compensation as of Fiscal Year 2013.

lpath inc-class a (HQ8A) Key Developments

Lpath Inc. - Shareholder/Analyst Call

To update investors on the progress of Lpath's programs

Lpath Inc. Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain

Lpath Inc. announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards. Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.

Lpath Inc. - Special Call

To update on the progress of the Nexus trial as well as other programs

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HQ8A:GR €2.21 EUR +0.018

HQ8A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HQ8A.
View Industry Companies
 

Industry Analysis

HQ8A

Industry Average

Valuation HQ8A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.6x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LPATH INC-CLASS A, please visit www.lpath.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.